Drugs / LCAR-T2C
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04219319 | Dec 2021 → Jul 2022 | T-cell and NK-cell neoplasm | The First Affiliated Hospital with Nanjing Medical University | Terminated | No outcome recorded |
| Phase 1 | NCT04973527 | Jul 2021 → Jul 2022 | T-cell leukemia, T-cell non-Hodgkin lymphoma | Beijing Boren Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-T2C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04219319 ↗ |
| Modality | Cell therapy | “LCAR-T2C CAR-T cells” NCT04219319 ↗ |
| Target | CD4 | “CD4-directed CAR-T cells” NCT04219319 ↗ |